In the third installment of our series on preparedness, Gavin Harris, MD, discusses the principles and challenges of biorisk management, focusing on infectious disease threats and containment strategies.

Caryn Fenner and Petro Terblanche outline Afrigen's clinical trial plans, local partnerships, and vaccine pipeline.

The COVID-19 pandemic underscored the urgent need for global pandemic preparedness. The World Health Organization (WHO) is leading efforts to establish a global treaty to address future pandemics, with findings expected in 2025. Central to this preparedness is immunomics, a field leveraging advanced genomics technologies to study the immune system at unprecedented levels of detail.

Roche's cobas liat molecular tests for chlamydia, gonorrhea, and Mycoplasma genitalium provide fast, accurate diagnoses in under 20 minutes.

Review finds Long COVID patients experience executive function impairments impacting tasks like shifting, inhibition, and working memory, affecting daily activities.

This investment will support the development of a rapid diagnostic platform for neonatal sepsis care by identifying infections and resistance markers within hours.

Promptly vaccinating the "ring" of contacts and contacts-of-contacts along with standard infection control measures interrupted Ebola transmission in the DRC.

Significant value can be offered through the incorporation of stewardship concepts into infection guidelines, but we must also address the risk and challenges it may impose on health care systems.

Following up on the goal, set in 2015, to diagnose 95% and treat 95% of serious fungal infections by year-end 2025.

Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.

Growing threat of beta-lactamase resistance genes across human and animal health, efforts to reduce HIV disparities for Black women, the "skip phenomenon" in S lugdunensis endocarditis, and more.

Mary Rochelle Smith, MD, Julie J Lee, MD, and Amy Chang, MD, PharmD, share expert strategies for implementing effective clinical decision support tools in practice.

Study shows 2′-fucosyllactose, a sugar in human milk, could reduce norovirus replication, offering hope for new treatments amid rising cases.

The federal agency is asking hospitalists and labs to accelerate this process in order to know if they are dealing with avian influenza.

In persons living with HIV and diabetes, the management of diabetes is lagging behind the evidence. Despite SGLT-2 inhibitors demonstrating robust clinical data in the general population, they are grossly underused in persons with HIV and diabetes.

Patrick D Crowley, DO explains the impact of the "skip phenomenon" in Staphylococcus lugdunensis infective endocarditis, linking it to longer hospital stays and higher mortality rates.

A new treatment of albendazole and ivermectin shows higher efficacy against Trichuris trichiura and hookworm infections, offering a new treatment approach for soil-transmitted worms.

These types of infections will continue to rise, and there is a need to understand what we are witnessing and find ways to combat them.

Babafela Awosile, DVM, MVSc, PhD, DACVPM, discusses the need for surveillance as blaCTX-M-15 and blaCMY-2 spread in humans, animals, and the environment.

The Phase 1 clinical trial for ARCT-2304, a self-amplifying mRNA vaccine, seeks to address pandemic influenza risk as H5N1 cases increase.

The choice between debridement and implant exchange affects treatment outcomes for Candida-related prosthetic joint infections, highlighting the need for standardized guidelines and further research.

How targeting zinc deprivation in VIM-2-expressing bacteria may open new doors for treating multidrug-resistant infections, with azithromycin showing promise.

Study questions whether reducing antibiotic treatment duration for pneumococcal bacteremia still ensures effective outcomes and minimizes risks.

Between those infected and uninfected with COVID-19, investigators observed no differences in symptom trajectories, assessed through SymptoMScreen.

Findings from a recent phase 3 trial show promising results for the approval of ziresovir in the treatment of respiratory syncytial virus in infants.